Clinical Trial

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Study acronym: SunStone
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-08-14; most recent amendment 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2024-09-24
Trial Details
NCT Number NCT06559163
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Systemic Lupus Erythematosus
Enrollment 190 participants
Start Date 2024-09-17
Primary Completion 2026-06 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-30